AI Article Synopsis
- Lnc-IL7R is a long non-coding RNA that plays a crucial role in regulating inflammation and has been investigated for its potential as a biomarker in acute respiratory distress syndrome (ARDS).
- The study involved comparing plasma levels of lnc-IL7R in 85 ARDS patients and 49 healthy controls, revealing that lnc-IL7R levels were significantly lower in ARDS patients, particularly in severe cases, and correlated with disease severity.
- The findings suggest that lnc-IL7R could serve as a reliable biomarker for diagnosing ARDS and predicting the 28-day mortality rate among affected individuals.
Article Abstract
Background: Long non-coding RNAs (lncRNAs) regulate a variety of genes and biological processes. Lnc-IL7R plays a considerable role in the regulation of inflammation, but its prognostic potential in acute respiratory distress syndrome (ARDS) has not been fully explained. In this study, the role of lnc-IL7R as a potential biomarker in ARDS was examined.
Objective: Role of lnc-IL7R as potential biomarker in ARDS.
Methods: LncRNA-IL7R was isolated from the plasma of patients with ARDS and healthy controls and clinical indexes were obtained within 24 h after admission. The relative expression of lnc-IL7R was obtained by quantitative real-time PCR. The correlations between lnc-IL7R and continuous variables in ARDS were tested using Spearman's coefficients.
Results: A total of 85 ARDS patients and 49 healthy controls were included. Plasma lnc-IL7R was significantly down-regulated in ARDS compared with the levels in healthy control individuals, especially in severe ARDS (P < .01). The area under the curve (AUC) of lnc-IL7R for ARDS diagnosis was 0.87 (sensitivity 75.3%, specificity 93.9%). The lnc-IL7R levels were correlated with the severity of ARDS (ρ = -0.31, P = .0215), oxygenation index (ρ = 0.61, P < .001), APACHE II score (ρ = -0.04, P = .0230), CRP (ρ = -0.26, P = .0148) and WBC (ρ = -0.29, P = .0064). Lnc-IL7R relative value ≥ 0.33 showed the lower 28-day mortality in the patients with ARDS(P < .05).The survivors showed higher lnc-IL7R level and lower APACHE II score, SOFA score and length of mechanical ventilation than in the non-survivors (P = .0109, P < .001, P < .001 and P = .017, respectively).
Conclusions: Lnc-IL7R is a novel biomarker for the diagnosis of ARDS and predicts the severity of ARDS and 28-day mortality in this patients cohort.
Trial Registration: The study was registered with the Chinese Clinical Trial Registry (ChiCTR-DOD-16008657).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/crj.12717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cell-cell crosstalk in the pathogenesis of acute lung injury and acute respiratory distress syndrome.
Tissue Barriers
January 2025
Sepsis Translational Medicine Key Laboratory of Hunan Province, Department of Pathophysiology, School of Basic Medicine Science, Central South University, Changsha, Hunan, PR China.
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the result of an exaggerated inflammatory response triggered by a variety of pulmonary and systemic insults. The lung tissues are comprised of a variety of cell types, including alveolar epithelial cells, pulmonary vascular endothelial cells, macrophages, neutrophils, and others. There is mounting evidence that these diverse cell populations within the lung interact to regulate lung inflammation in response to both direct and indirect stimuli.
View Article and Find Full Text PDFThyroid storm presenting with acute respiratory distress syndrome in a postpartum patient: a case report.
Intern Emerg Med
January 2025
Department of Emergency Medicine, Ataturk Sanatoryum Training and Research Hospital, Ankara, Turkey.
Predictive Potential of ECMO Blood Flow for Hemolysis and Outcome of Patients with Severe ARDS.
J Clin Med
December 2024
Department of Anesthesiology and Intensive Care Medicine CCM/CVK Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
Treatment with veno-venous extracorporeal membrane oxygenation (VV ECMO) has become a frequently considered rescue therapy in patients with severe acute respiratory distress syndrome (ARDS). Hemolysis is a common complication in patients treated with ECMO. Currently, it is unclear whether increased ECMO blood flow (Q̇) contributes to mortality and might be associated with increased hemolysis.
View Article and Find Full Text PDFRecent Advances and Future Directions in Extracorporeal Carbon Dioxide Removal.
J Clin Med
December 2024
Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London SE1 9RT, UK.
Extracorporeal carbon dioxide removal (ECCOR) is an emerging technique designed to reduce carbon dioxide (CO) levels in venous blood while enabling lung-protective ventilation or alleviating the work of breathing. Unlike high-flow extracorporeal membrane oxygenation (ECMO), ECCOR operates at lower blood flows (0.4-1.
View Article and Find Full Text PDFRegulatory Roles of Noncanonical Inflammasomes in Inflammatory Lung Diseases.
Int J Mol Sci
December 2024
Department of Life Sciences, Kyonggi University, Suwon 16227, Republic of Korea.
The inflammatory response consists of two stages: priming and triggering. The triggering stage is marked by the activation of inflammasomes, which are cytosolic protein complexes acting as platforms for inflammation. Inflammasomes are divided into canonical and noncanonical categories.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!